SkinNCT07298382
See the Impact Beem's Blue Light Therapy Has on Your Skin Health!
A study testing Blue Light Therapy in people with Skin, run by Efforia, Inc at 1 site in United States.
Trial summary
Participants will experience a rejuvenating twice-weekly light therapy journey that blends the power of blue, red, and infrared light. Each 20-minute session flows through three phases: starting with refreshing blue light to awaken and energize, then moving into soothing red light, and finishing with deeply nourishing… Read more about this study
- Who is it for?
- Any ageHealthy volunteers can take part
- Conditions the study is for
- Skin
- What is being tested?
- Blue Light Therapy
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 100 participants
- Where
- 1 siteUnited States
- Study dates
- 6 Oct 2025to 6 Oct 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Who may be able to join
- Can read and understand English.
- US resident.
- Willing and able to follow the requirements of the protocol.
Who cannot join
- Individuals with Epilepsy
- Individuals with Photosensitivity
- Individuals with eye conditions
- Pregnant individuals
- Individuals with skin sensitivity
- Individuals taking certain light-sensitive medications
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Efforia
New York, New York, 10003
Matthew Amsden, (646) 679-2479, help@efforia.com
About this study
Participants will experience a rejuvenating twice-weekly light therapy journey that blends the power of blue, red, and infrared light. Each 20-minute session flows through three phases: starting with refreshing blue light to awaken and energize, then moving into soothing red light, and finishing with deeply nourishing infrared light. This unique protocol is designed to help unlock healthier-looking skin and boost your natural glow.
Read the detailed description
Treatment activities:
Twice a week, for 20 minutes, participants will undergo exposure to blue, red, and infrared light as part of the light therapy treatment.
Assesments and frequency:
Comprehensive Weekly Skin Health Self-Assessment: Conducted weekly. Dermatology Life Quality Index (DLQI): Conducted during the study. Facial Skin Self-Assessment Survey: Conducted during the study. Pre/Post Photos of Participants' Skin: Conducted at the beginning and end of the study.
Methodology:
The study entitled "See the Impact Beem's Blue Light Therapy Has on Your Skin Health!" aims to evaluate the effectiveness of a light therapy regimen on improving skin health. This single-arm observational trial, conducted under Efforia's Signal Phase study design, involves participants undergoing a twice-weekly, 20-minute light therapy session. Each session is structured into three phases: starting with blue light, transitioning to red light, and concluding with infrared light, each targeting different aspects of skin health. By allowing participants to act as their own control, the trial will provide initial insights into the potential benefits of this therapy for enhancing skin appearance and health, with a focus on gathering preliminary efficacy and safety data.
The study's methodology is designed to assess how these light therapies influence skin conditions through a series of personalized assessments and feedback mechanisms. Participants will engage in various self-assessment tasks, including a Comprehensive Weekly Skin Health Self-Assessment, Dermatology Life Quality Index (DLQI) surveys, and Facial Skin Self-Assessment Surveys. These tasks are complemented by pre- and post-therapy photographic documentation to visually track skin changes. By collecting this data, the trial seeks to discern patterns and indications of improvement in skin health, potentially providing a directional indication of positive results from the intervention.
- Conditions
- Skin
- Being tested
- Blue Light Therapy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Blue Light TherapyDevice
Blue Light Therapy therapy, combining blue, red, and infrared light, has been backed by studies showing improved skin health and reduced signs of aging. The medical community generally supports light therapy for its non-invasive nature and potential benefits, though results can vary. Social media buzz highlights glowing testimonials, while the general population views it as a promising skincare enhancement with minimal risks. Benefits include improved complexion and reduced acne, with risks being rare and minor, such as temporary redness.
Treatment:
First 5 Minutes 450nm (Blue) Second 5 Minutes 450nm (Blue) 660nm (Red) 810nm (Infrared) Final 10 Minutes 660nm (Red) 810nm (Infrared)
| Study group | Role | What they receive |
|---|---|---|
| Single Arm longitudinal where participants act as their own control | Experimental | Single Arm longitudinal where participants act as their own control Receives: Device: Blue Light Therapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Comprehensive Weekly Skin Health Self-Assessment
The Comprehensive Weekly Skin Health Self-Assessment is designed to meticulously evaluate various aspects of skin health, including clarity, breakouts, pore size, redness, moisture, sensitivity, and signs of aging. This detailed survey allows individuals to track changes weekly, providing insights into the effectiveness of their skincare routines and the impact of lifestyle choices on their skin's condition. By regularly monitoring a wide range of skin health indicators, users can make informed adjustments to their skincare practices, aiming for optimal skin health. The survey fosters a proactive approach to skincare, emphasizing the importance of observation and adjustment based on personal skin behavior.
Scoring scale 0-75 Interpretation Higher score is associated with better perceived skin health Lower score is associated with worse perceived skin health
Measured: Baseline through Day 30 (weekly assessments)
Dermatology Life Quality Index (DLQI)
The Dermatology Life Quality Index (DLQI) is a survey designed to measure the impact of skin-related issues on the quality of life over the past week. It assesses various dimensions of daily living, from personal discomfort to social interactions, influenced by skin conditions. This index is valuable for both patients and healthcare providers to understand the severity and emotional toll of dermatological issues. By quantifying the effects on daily activities and personal relationships, the DLQI helps in guiding treatment decisions and measuring treatment outcomes.
Scoring Range
Minimum score: 0
Maximum score: 30
Each of the 10 items is scored from 0 to 3, yielding a total score between 0 and 30.
Score Interpretation
Higher scores indicate worse outcomes, meaning a greater negative impact of skin disease on a participant's quality of life.
Measured: Baseline through Day 30 (weekly assessments)
Facial Skin Self-Assessment Survey
The Comprehensive Weekly Skin Health Self-Assessment is designed to meticulously evaluate various aspects of skin health, including clarity, breakouts, pore size, redness, moisture, sensitivity, and signs of aging. This detailed survey allows individuals to track changes weekly, providing insights into the effectiveness of their skincare routines and the impact of lifestyle choices on their skin's condition. By regularly monitoring a wide range of skin health indicators, users can make informed adjustments to their skincare practices, aiming for optimal skin health. The survey fosters a proactive approach to skincare, emphasizing the importance of observation and adjustment based on personal skin behavior.
Scoring scale 0-75 Interpretation Higher score is associated with better perceived skin health Lower score is associated with worse perceived skin health
Measured: Baseline through day 30 (weekly assessments)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Dec 2025
- Study start6 Oct 2025
- Primary completion6 Oct 2026 (estimated)
- Study completion6 Oct 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for SkinStudies of the same condition, open and under way.
- More trials run by Efforia, IncThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Efforia, Inc
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07298382
- Sponsor's protocol ID
- 46140
- Status last verified
- Nov 2025
- First submitted
- 5 Dec 2025
- Last updated
- 23 Dec 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 23 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- See the Impact Beem's Blue Light Therapy Has on Your Skin Health!
- ClinicalTrials.gov ID
- NCT07298382
- Acronym / sponsor ID
- 46140
- Conditions
- Skin
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Efforia, IncIndustry (pharma, biotech, devices)
- Study start
- 6 Oct 2025 (actual)
- Primary completion
- 6 Oct 2026 (estimated)
- Study completion
- 6 Oct 2026 (estimated)
- First posted
- 23 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Participants will experience a rejuvenating twice-weekly light therapy journey that blends the power of blue, red, and infrared light. Each 20-minute session flows through three phases: starting with refreshing blue light to awaken and energize, then moving into soothing red light, and finishing with deeply nourishing infrared light. This unique protocol is designed to help unlock healthier-looking skin and boost your natural glow.
Detailed description
Treatment activities:
Twice a week, for 20 minutes, participants will undergo exposure to blue, red, and infrared light as part of the light therapy treatment.
Assesments and frequency:
Comprehensive Weekly Skin Health Self-Assessment: Conducted weekly. Dermatology Life Quality Index (DLQI): Conducted during the study. Facial Skin Self-Assessment Survey: Conducted during the study. Pre/Post Photos of Participants' Skin: Conducted at the beginning and end of the study.
Methodology:
The study entitled "See the Impact Beem's Blue Light Therapy Has on Your Skin Health!" aims to evaluate the effectiveness of a light therapy regimen on improving skin health. This single-arm observational trial, conducted under Efforia's Signal Phase study design, involves participants undergoing a twice-weekly, 20-minute light therapy session. Each session is structured into three phases: starting with blue light, transitioning to red light, and concluding with infrared light, each targeting different aspects of skin health. By allowing participants to act as their own control, the trial will provide initial insights into the potential benefits of this therapy for enhancing skin appearance and health, with a focus on gathering preliminary efficacy and safety data.
The study's methodology is designed to assess how these light therapies influence skin conditions through a series of personalized assessments and feedback mechanisms. Participants will engage in various self-assessment tasks, including a Comprehensive Weekly Skin Health Self-Assessment, Dermatology Life Quality Index (DLQI) surveys, and Facial Skin Self-Assessment Surveys. These tasks are complemented by pre- and post-therapy photographic documentation to visually track skin changes. By collecting this data, the trial seeks to discern patterns and indications of improvement in skin health, potentially providing a directional indication of positive results from the intervention.
Study design
- Primary purpose
- Health services research
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Single Arm longitudinal where participants act as their own control | Experimental | Device: Blue Light TherapySingle Arm longitudinal where participants act as their own control |
Who may qualify
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (3 listed)
- Can read and understand English.
- US resident.
- Willing and able to follow the requirements of the protocol.
Key exclusion criteria (6 listed)
- Individuals with Epilepsy
- Individuals with Photosensitivity
- Individuals with eye conditions
- Pregnant individuals
- Individuals with skin sensitivity
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Blue Light TherapyBlue Light Therapy therapy, combining blue, red, and infrared light, has been backed by studies showing improved skin health and reduced signs of aging. The medical community generally supports light therapy for its non-invasive nature and potential benefits, though results can vary. Social media buzz highlights glowing testimonials, while the general population views it as a promising skincare enhancement with minimal risks. Benefits include improved complexion and reduced acne, with risks being rare and minor, such as temporary redness. Treatment: First 5 Minutes 450nm (Blue) Second 5 Minutes 450nm (Blue) 660nm (Red) 810nm (Infrared) Final 10 Minutes 660nm (Red) 810nm (Infrared) | Device | Single Arm longitudinal where participants act as their own control |
Primary outcome
Comprehensive Weekly Skin Health Self-Assessment
Time frame: Baseline through Day 30 (weekly assessments)
The Comprehensive Weekly Skin Health Self-Assessment is designed to meticulously evaluate various aspects of skin health, including clarity, breakouts, pore size, redness, moisture, sensitivity, and signs of aging. This detailed survey allows individuals to track changes weekly, providing insights into the effectiveness of their skincare routines and the impact of lifestyle choices on their skin's condition. By regularly monitoring a wide range of skin health indicators, users can make informed adjustments to their skincare practices, aiming for optimal skin health. The survey fosters a proactive approach to skincare, emphasizing the importance of observation and adjustment based on personal skin behavior. Scoring scale 0-75 Interpretation Higher score is associated with better perceived skin health Lower score is associated with worse perceived skin health
Dermatology Life Quality Index (DLQI)
Time frame: Baseline through Day 30 (weekly assessments)
The Dermatology Life Quality Index (DLQI) is a survey designed to measure the impact of skin-related issues on the quality of life over the past week. It assesses various dimensions of daily living, from personal discomfort to social interactions, influenced by skin conditions. This index is valuable for both patients and healthcare providers to understand the severity and emotional toll of dermatological issues. By quantifying the effects on daily activities and personal relationships, the DLQI helps in guiding treatment decisions and measuring treatment outcomes. Scoring Range Minimum score: 0 Maximum score: 30 Each of the 10 items is scored from 0 to 3, yielding a total score between 0 and 30. Score Interpretation Higher scores indicate worse outcomes, meaning a greater negative impact of skin disease on a participant's quality of life.
Facial Skin Self-Assessment Survey
Time frame: Baseline through day 30 (weekly assessments)
The Comprehensive Weekly Skin Health Self-Assessment is designed to meticulously evaluate various aspects of skin health, including clarity, breakouts, pore size, redness, moisture, sensitivity, and signs of aging. This detailed survey allows individuals to track changes weekly, providing insights into the effectiveness of their skincare routines and the impact of lifestyle choices on their skin's condition. By regularly monitoring a wide range of skin health indicators, users can make informed adjustments to their skincare practices, aiming for optimal skin health. The survey fosters a proactive approach to skincare, emphasizing the importance of observation and adjustment based on personal skin behavior. Scoring scale 0-75 Interpretation Higher score is associated with better perceived skin health Lower score is associated with worse perceived skin health
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Dec 2025.
Related trials for Skin
Not yet recruitingPhase 2
Extension Study of Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis (CDDY391A12201-extension)
Moderate to Severe Psoriatic Arthritis
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingPhase 1
IL-17 Blockade to Decrease irAEs (REPLAY)
Metastatic Melanoma
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 2
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
Invasive Mammary Carcinoma, Metastatic Breast Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Blue Light Therapy in people with Skin, run by Efforia, Inc at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 23 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Matthew Amsden ((646) 679-2479, help@efforia.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Comprehensive Weekly Skin Health Self-Assessment (time frame: Baseline through Day 30 (weekly assessments)). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Dec 2025.